Trial Profile

Nivolumab in 2nd Line or More for Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Bone metastases; Brain metastases; Liver metastases; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms ERORECI

Most Recent Events

21 Sep 2020 Results association between sites of metastatic disease and clinical outcomes in NSCLC patients treated by Nivolumab, presented at the 45th European Society for Medical Oncology Congress
10 Oct 2018 New trial record
26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com